登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，3月24日，COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence?》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-03-25

  • COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

    What Is the Evidence?

    Ankit B. Patel, MD, PhD1; Ashish Verma, MBBS1

    JAMA. Published online March 24, 2020. doi:10.1001/jama.2020.4812

    Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The particularly infectious capacity of the virus, along with mortality rates ranging from 1% to above 5%, has raised concerns across the globe.1 Older patients with comorbid conditions including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with even higher mortality rates, suggesting particularly susceptible populations.

  • 原文来源：https://jamanetwork.com/journals/jama/fullarticle/2763803?resultClick=1
162浏览量
原文链接
相关报告

  • 《JAMA，5月5日，Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-06
    • Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) Neil Mehta, MBBS1; Ankur Kalra, MD2,3; Amy S. Nowacki, PhD4; et alScott Anjewierden, BS1; Zheyi Han, BS1; Pavan Bhat, MD2; Andres E. Carmona-Rubio, MD2; Miriam Jacob, MD2; Gary W. Procop, MD5; Susan Harrington, PhD5; Alex Milinovich, BA4; Lars G. Svensson, MD, PhD6; Lara Jehi, MD7; James B. Young, MD1,2; Mina K. Chung, MD2,8 Author Affiliations Article Information JAMA Cardiol. Published online May 5, 2020. doi:10.1001/jamacardio.2020.1855 Abstract Importance The role of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in the setting of the coronavirus disease 2019 (COVID-19) pandemic is hotly debated. There have been recommendations to discontinue these medications, which are essential in the treatment of several chronic disease conditions, while, in the absence of clinical evidence, professional societies have advocated their continued use. Objective To study the association between use of ACEIs/ARBs with the likelihood of testing positive for COVID-19 and to study outcome data in subsets of patients taking ACEIs/ARBs who tested positive with severity of clinical outcomes of COVID-19 (eg, hospitalization, intensive care unit admission, and requirement for mechanical ventilation).
    111浏览量
    原文链接

  • 《JAMA，4月3日，Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-06
    • Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers Chirag Bavishi, MD, MPH1; Thomas M. Maddox, MD, MSc2,3; Franz H. Messerli, MD4,5,6 Author Affiliations Article Information JAMA Cardiol. Published online April 3, 2020. doi:10.1001/jamacardio.2020.1282 The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality inflicted by the severe acute respiratory syndrome (SARS) epidemic of 2002 and 2003 and the Middle East respiratory syndrome (MERS) epidemic of 2013. The pandemic is spreading at an exponential rate, with millions of people across the globe at risk of contracting SARS-CoV-2. Initial reports suggest that hypertension, diabetes, and cardiovascular diseases were the most frequent comorbidities in affected patients, and case fatality rates tended to be high in these individuals. In the largest Chinese study to date,1 which included 44?672 confirmed cases, preexisting comorbidities that had high mortality rates included cardiovascular disease (10.5%), diabetes (7.3%), and hypertension (6.0%). Patients with such comorbidities are commonly treated with renin angiotensin system blockers, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).
    110浏览量
    原文链接